7:04AM Agenus: Clinical data published in vaccine demonstrate robust immune response with Agenus' Herpes vaccine containing qs-21 adjuvant (AGEN) 0.56 : All patients who were evaluable for immune response and received HerpV showed a statistically significant CD4+ T cell response (100%; 7/7) to HSV-2 antigens as detected by IFNy Elispot, and the majority of those patients demonstrated a CD8+ T cell response (75%; 6/8). The vaccine was well tolerated, with injection site pain as the most commonly reported adverse event.
Market Data 
Markets 
AI
